Epigenetic Modification of As a Novel Biomarker for the Prognosis of Early Stage Head and Neck Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2018 Mar 28

PMID 29581773

Citations 11

Authors

Kiyoshi Misawa

Yuki Misawa

Atsushi Imai

Daiki Mochizuki

Shiori Endo

Masato Mima

Ryuji Ishikawa

Hideya Kawasaki

Takashi Yamatodani

Takeharu Kanazawa

Affiliations

Soon will be listed here.

Abstract

This study examined ( methylation profiles in head and neck squamous-cell carcinoma (HNSCC) patients at diagnosis and follow-up, and evaluated their prognostic significance and value as a biomarker. expression was examined in a panel of cell lines by quantitative reverse transcription PCR (qRT-PCR). Promoter methylation was determined by quantitative methylation-specific polymerase chain reaction (qMSP) and was compared to the clinical characteristics of 205 samples. promoter methylation was associated with transcriptional inhibition and was correlated with disease recurrence in 31.7% of cases, with an odds ratio of 1.694 (95% confidence interval: 1.093-2.626; P = 0.018) by multivariate Cox proportional hazard regression analysis. promoter hypermethylation showed highly discriminatory receiver operator characteristic curve profiles that clearly distinguished HNSCC from adjacent normal mucosal tissue, and was correlated with reduced disease-free survival in early stage T1 and T2 patients (log-rank test, P < 0.001). methylation was significantly correlated with the methylation status of both and . This study suggests that CpG hypermethylation is a likely mechanism of gene inactivation, supporting the hypothesis that might play a role in HNSCC tumorigenesis and could serve as an important biomarker.

Citing Articles

TREMSUCS-TCGA - an integrated workflow for the identification of biomarkers for treatment success.

Balogh G, Jorge N, Dupain C, Kamal M, Servant N, Le Tourneau C J Integr Bioinform. 2024; 21(4).

PMID: 39654143 PMC: 11698617. DOI: 10.1515/jib-2024-0031.

Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.

Zakari S, Niels N, Olagunju G, Nnaji P, Ogunniyi O, Tebamifor M Front Oncol. 2024; 14:1405267.

PMID: 39132504 PMC: 11313249. DOI: 10.3389/fonc.2024.1405267.

Accurate prediction of pan-cancer types using machine learning with minimal number of DNA methylation sites.

Ning W, Wu T, Wu C, Wang S, Tao Z, Wang G J Mol Cell Biol. 2023; 15(4).

PMID: 37037781 PMC: 10635511. DOI: 10.1093/jmcb/mjad023.

SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.

Sun B, Xu L, Bi W, Ou W Int J Mol Sci. 2022; 23(4).

PMID: 35216168 PMC: 8876671. DOI: 10.3390/ijms23042053.

SALL Proteins; Common and Antagonistic Roles in Cancer.

Alvarez C, Quiroz A, Benitez-Riquelme D, Riffo E, Castro A, Pincheira R Cancers (Basel). 2021; 13(24).

PMID: 34944911 PMC: 8699250. DOI: 10.3390/cancers13246292.

References

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View

Lin J, Qian J, Yao D, Qian W, Yang J, Wang C . Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome. Leuk Res. 2012; 37(1):71-5. DOI: 10.1016/j.leukres.2012.10.014. View

Hill V, Hesson L, Dansranjavin T, Dallol A, Bieche I, Vacher S . Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer. 2010; 9:51. PMC: 2841122. DOI: 10.1186/1476-4598-9-51. View

Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski N, Gautier E . Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol. 2016; 17(12):1397-1406. DOI: 10.1038/ni.3585. View

Misawa K, Kanazawa T, Misawa Y, Imai A, Endo S, Hakamada K . Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer. Cancer Biomark. 2012; 10(3-4):135-44. DOI: 10.3233/CBM-2012-0242. View

Kristensen L, Mikeska T, Krypuy M, Dobrovic A . Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res. 2008; 36(7):e42. PMC: 2367707. DOI: 10.1093/nar/gkn113. View

Basta J, Robbins L, Kiefer S, Dorsett D, Rauchman M . Sall1 balances self-renewal and differentiation of renal progenitor cells. Development. 2014; 141(5):1047-58. PMC: 3929412. DOI: 10.1242/dev.095851. View

Park H, Kim M, Yamashita K, Westra W, Carvalho A, Lee J . DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer. 2008; 122(11):2498-502. DOI: 10.1002/ijc.23434. View

Misawa K, Mochizuki D, Imai A, Misawa Y, Endo S, Mima M . Epigenetic silencing of is an independent predictor of poor survival in head and neck cancer. Clin Epigenetics. 2017; 9:64. PMC: 5469057. DOI: 10.1186/s13148-017-0363-1. View

10.

Barry J, Reddy M . The association of an epibulbar dermoid and Duane syndrome in a patient with a SALL1 mutation (Townes-Brocks Syndrome). Ophthalmic Genet. 2008; 29(4):177-80. DOI: 10.1080/13816810802354224. View

11.

Yang X, Sun J, Li F, Wu Y, Du H, Zhu W . Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma. World J Gastroenterol. 2012; 18(21):2719-26. PMC: 3370011. DOI: 10.3748/wjg.v18.i21.2719. View

12.

Ma Y, Singer D, Gozman A, Ford D, Chai L, Steinhoff M . Hsal 1 is related to kidney and gonad development and is expressed in Wilms tumor. Pediatr Nephrol. 2001; 16(9):701-9. DOI: 10.1007/s004670100624. View

13.

Netzer C, Bohlander S, Hinzke M, Chen Y, Kohlhase J . Defining the heterochromatin localization and repression domains of SALL1. Biochim Biophys Acta. 2006; 1762(3):386-91. DOI: 10.1016/j.bbadis.2005.12.005. View

14.

Buck A, Kispert A, Kohlhase J . Embryonic expression of the murine homologue of SALL1, the gene mutated in Townes--Brocks syndrome. Mech Dev. 2001; 104(1-2):143-6. DOI: 10.1016/s0925-4773(01)00364-1. View

15.

Novo C, Tang C, Ahmed K, Djuric U, Fussner E, Mullin N . The pluripotency factor Nanog regulates pericentromeric heterochromatin organization in mouse embryonic stem cells. Genes Dev. 2016; 30(9):1101-15. PMC: 4863740. DOI: 10.1101/gad.275685.115. View

16.

Kalari S, Pfeifer G . Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet. 2010; 70:277-308. PMC: 2951285. DOI: 10.1016/B978-0-12-380866-0.60010-1. View

17.

Sung C, Li D, Andrews E, Drapkin R, Benjamin T . Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. Mol Oncol. 2013; 7(3):419-27. PMC: 5528472. DOI: 10.1016/j.molonc.2012.11.005. View

18.

Sato A, Kishida S, Tanaka T, Kikuchi A, Kodama T, Asashima M . Sall1, a causative gene for Townes-Brocks syndrome, enhances the canonical Wnt signaling by localizing to heterochromatin. Biochem Biophys Res Commun. 2004; 319(1):103-13. DOI: 10.1016/j.bbrc.2004.04.156. View

19.

Zhang J, Tam W, Tong G, Wu Q, Chan H, Soh B . Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol. 2006; 8(10):1114-23. DOI: 10.1038/ncb1481. View

20.

Liu C, Wu H, Li Y, Shen L, Yu R, Yin H . SALL4 suppresses PTEN expression to promote glioma cell proliferation via PI3K/AKT signaling pathway. J Neurooncol. 2017; 135(2):263-272. PMC: 5663806. DOI: 10.1007/s11060-017-2589-3. View